TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03311594
Drug: Low Alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Alcohol Consumption
Study: NCT00592215
Drug: Experimental (mifepristone and misoprostol)
Normalized name: naproxen and misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
Study: NCT03311594
Drug: Placebo Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Alcohol Consumption
Study: NCT02559440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff in each nostril every evening
Study: NCT02559440
Drug: Placebo + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff of placebo +1 puff of Placebo in each nostril every evening
Study: NCT04540042
Drug: Placebo (Part 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V., multiple-dose (Day 1 and Day 22)
Study: NCT04540042
Drug: Placebo (Part 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V., single-dose (Day 1)
Study: NCT03776058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT03374176
Drug: Clindamycin 300 mg
Normalized name: clindamycin 300 MG
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were instructed to take a capsule three times a day for 7 days
Study: NCT01881464
Drug: Anti TNF Alfa.
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
Study: NCT01248975
Drug: FP/SAL 250/50mcg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/SAL 250/50mcg BID
Study: NCT01248975
Drug: GSK2190915 200mg QD (AM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 200mg QD (AM)
Study: NCT02821715
Drug: THN102 300/3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04081350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01248975
Drug: GSK2190915 100mg QD (AM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 100mg QD (AM)
Study: NCT01248975
Drug: Placebo tablets (2) (AM)
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (2) (AM)
Study: NCT01248975
Drug: Placebo capsule (PM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (PM)
Study: NCT02788747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo administered once daily for 28 consecutive days
Study: NCT01290380
Drug: ASA404, DMXAA, DXAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
Study: NCT03456752
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 1.6ml intravenously prior to induction of anesthesia
Study: NCT01223703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
Study: NCT02911701
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00784654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once per day (double-blind period)
Study: NCT03458208
Drug: Glucophage®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition
Study: NCT03458208
Drug: Glucophage®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition
Study: NCT03740971
Drug: Guideline-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based therapy
Study: NCT02911701
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00910221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT03263507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline .9%
Study: NCT02504333
Drug: m-FOLFOX
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 28 according to the dose levels stablished in Phase I
Study: NCT03222206
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Medicate salsalate 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month
Study: NCT00827021
Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU/week I.V. Until the end of the trial
Study: NCT00827021
Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18000 IU/week I.V. Until the end of the trial
Study: NCT04676997
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
Study: NCT00964327
Drug: TMC114
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01208714
Drug: Optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c \< 6.5%).
Study: NCT01040455
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily for eight weeks
Study: NCT04342975
Drug: Nicotinamide Riboside + Pterostilbene
Normalized name: nicotinamide ribotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
Study: NCT04342975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
Study: NCT00631748
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
Study: NCT00741780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04489641
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological intervention
Study: NCT01983969
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg by vein or mouth three times a day from Day -1.
Study: NCT00939900
Drug: zoledronic acid (aclasta)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
Study: NCT01258907
Drug: MLDL1278A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose
Study: NCT01258907
Drug: MLDL1278A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating intravenous dose
Study: NCT02709018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01258907
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating intravenous dose
Study: NCT01258907
Drug: statin, stable dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating oral dose
Study: NCT00711386
Drug: GSK706769
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg, 100mg, 200mg, or 400mg
Study: NCT01054742
Drug: Standard of Care PegIntron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
Study: NCT03138538
Drug: Part 1: M8891
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Study: NCT00290615
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00879229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ambrisentan administered orally once daily.
Study: NCT00836576
Drug: Lotensin® 40 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 40 mg, single-dose fasting
Study: NCT01240642
Drug: ASA404
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03615105
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg IV
Study: NCT04564053
Drug: LNA043
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection on Day 1
Study: NCT04564053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection on Day 1
Study: NCT00303628
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00303628
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01367145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules placebo per day
Study: NCT04623242
Drug: Matching Placebo (Gantenerumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo every 4 weeks
Study: NCT04623242
Drug: Matching Placebo (Solanezumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of placebo every 4 weeks
Study: NCT00278421
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00278421
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00019409
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00019409
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00019409
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00019409
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01414257
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
Study: NCT02823977
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded comparator administered to control arm
Study: NCT03733223
Drug: Ateptidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of ischemic stroke with Ateptidase
Study: NCT00115154
Drug: Aldara (imiquimod) cream, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02387359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03238781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
Study: NCT03175900
Drug: Naoan dripping pills
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）
Study: NCT03175900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)
Study: NCT00092222
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
Study: NCT00092222
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
Study: NCT00607308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo IV on Day 1
Study: NCT02572713
Drug: DaTSCAN™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02452190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01117636
Drug: Acetylsalicylic acid (Fast release Aspirin, BAY1019036)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter \[mL\]) between 14 hours post dental surgery.
Study: NCT01117636
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
Study: NCT01117636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
Study: NCT00193115
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193115
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00847912
Drug: Placebo, vehicle control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped.
Study: NCT03047070
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV normal saline infusion
Study: NCT00092222
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: if CD4 \< 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
Study: NCT02642653
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once per day dosing
Study: NCT01211249
Drug: GLPG0259 oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
Study: NCT03434405
Drug: Psychotropic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual delivered by patient's practitioner
Study: NCT01211249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
Study: NCT01211249
Drug: Placebo (Part B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
Study: NCT02597660
Drug: Bacteriostatic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, the diluent used to reconstitute somatropin
Study: NCT04044131
Drug: Sorbitol
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
Study: NCT01317589
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%
Study: NCT02378935
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily with food
Study: NCT01375920
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a matched placebo will be administered to patients to take twice a day for 3 weeks
Study: NCT02674880
Drug: HMW-HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerolized administration b.i.d.
Study: NCT01477983
Drug: Antiarrhythmic drug (AAD)
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
Study: NCT01957930
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
Study: NCT03840538
Drug: Probiotic Product - Cap
Normalized name: Rezyst Probiotic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
Study: NCT03627845
Drug: PHP-303
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT04507659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.
Study: NCT00000925
Drug: Optimune oral nutritional supplement
Normalized name: Optimmune
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02603003
Drug: JinFuKang
Approvals — FDA: no, EMA: no, PMDA: no
Description: po.tid.30ml
Study: NCT02920385
Drug: SNAC
Normalized name: Glucerna Snack Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily alone or together with levothyroxine or semaglutide
Study: NCT00857454
Drug: Testosterone MD-Lotion
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg to 120 mg administered topically once daily for 60 days
Study: NCT00077077
Drug: DJ-927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00077077
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00755313
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00755313
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02300103
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT00033917
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an anti-inflammatory drug
Study: NCT00033917
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline
Study: NCT01796171
Drug: 15 MBq/kg Betalutin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01796171
Drug: 20 MBq/kg Betalutin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02920385
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration alone or together with SNAC or oral semaglutide
Study: NCT01796171
Drug: 12.5 mBq/kg Betalutin
Approvals — FDA: no, EMA: no, PMDA: no